1719. Incidence and Characterization of Invasive Fungal Infections (IFIs) in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib (IBR)

BACKGROUND: IBR is a Bruton’s tyrosine kinase inhibitor, and plays a key role in the treatment of CLL. In randomized clinical trials, <1% of IBR-treated CLL patients developed IFIs. However, several IFIs were reported with real-life use of IBR. METHODS: This is a retrospective observational study...

詳細記述

保存先:
書誌詳細
出版年:Open Forum Infect Dis
主要な著者: Frei, Michael, Aitken, Samuel L, Jain, Nitin, Thompson, Philip, Wierda, William G, Kontoyiannis, Dimitrios P, DiPippo, Adam
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
Abstracts
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6808854/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1582
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料